Takeda Pharmaceutical (TSE:4502): Reassessing Valuation After Landmark Actos RICO Class Action Ruling
Takeda Pharmaceutical (TSE:4502) is back in the spotlight after the Ninth Circuit upheld a landmark civil RICO class action over alleged concealment of bladder cancer risks tied to its former diabetes blockbuster, Actos.
See our latest analysis for Takeda Pharmaceutical.
Despite the overhang from the Actos litigation, Takeda’s share price has held up reasonably well, with a 1 month share price return of 7.44% and a 1 year total shareholder return of 14.13%. This suggests sentiment is still cautiously constructive as investors also weigh new hematology data and recent partnership activity.
If this kind of risk reward balance interests you, it could be a good moment to scan other names in the space using our healthcare stocks for fresh ideas.
With litigation risk climbing but earnings and cash flows still growing, Takeda trades at a sizable intrinsic discount and modest upside to analyst targets, raising the question: is this a mispriced opportunity or is future growth already baked in?
Most Popular Narrative: 9.2% Undervalued
With Takeda closing at ¥4,491 against a narrative fair value of roughly ¥4,946, the story frames today’s price as lagging improving long term prospects.
The analysts have a consensus price target of ¥5056.071 for Takeda Pharmaceutical based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of ¥5900.0, and the most bearish reporting a price target of just ¥4500.0.
Want to see what drives this gap between modest revenue growth, sharply rising earnings, and a richer future multiple than peers? The full narrative unpacks the assumptions powering that valuation path.
Result: Fair Value of ¥4,946.14 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, sustained pricing pressure in key markets and faster than expected generic competition around Entyvio or Vyvanse could quickly undermine that upbeat valuation path.
Find out about the key risks to this Takeda Pharmaceutical narrative.
Build Your Own Takeda Pharmaceutical Narrative
If you see the risk reward picture differently or want to stress test your own assumptions, you can build a custom view in minutes: Do it your way.
A great starting point for your Takeda Pharmaceutical research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
Looking for more investment ideas?
Before markets move on without you, put Simply Wall Street’s tools to work and line up your next opportunities with targeted, data driven stock ideas.
- Capitalize on potential mispricings by scanning these 909 undervalued stocks based on cash flows that the market may be overlooking today.
- Tap into the AI boom by focusing on these 27 AI penny stocks positioned to benefit from accelerating adoption across industries.
- Lock in income potential by reviewing these 15 dividend stocks with yields > 3% that may boost your portfolio’s yield without stretching for risk.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com